The Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for patients with locally advanced or ...

Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

Erythromycin: This antibiotic is used for several types of infections, including skin and pneumonia.

Nidlegy is a fusion protein commercialized by Philogen, with a leading Phase III program in Metastatic Melanoma.

Evidence of metastatic spread should routinely be sought when examining patients. For patients with lesions less than 1 mm thick, close followup with biannual physical and skin examination is ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe —— Follows June 2024 European approval of FRUZAQLA® ...

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists and hematologists are contributors to groundbreaking breast cancer research studies being presented this week at the San ...

Regional lymph node involvement or systemic metastasis ... other malignant eyelid tumors, SGC may be associated with loss of lashes. SGC can invade and replace eyelid skin and conjunctival ...